Fibroblast Growth Factor Signaling In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Fibroblast Growth Factors (FGFs) are a family of growth factors critical for neural development, neurogenesis, synaptic plasticity, and neuronal survival. FGF signaling involves multiple receptor tyrosine kinases (FGFR1-4) and downstream pathways including MAPK/ERK, PI3K/Akt, and PLCγ. Dysregulation of FGF signaling contributes to neurodegenerative processes, while FGF therapy represents a potential neuroprotective strategy.
flowchart TD
A[FGF Ligand] --> B[FGFR1-4] -->
B --> C[FGFR1: Neurons, Stem Cells] -->
B --> D[FGFR2: Glia, Stem Cells] -->
B --> E[FGFR3: Neurons] -->
B --> F[FGFR4: Peripheral] -->
C --> G[FGFR Dimerization] -->
D --> G
E --> G
F --> G
G --> H[Autophosphorylation] -->
H --> I[FRS2α/β Adapter] -->
H --> J[PLCγ] -->
I --> K[RAS/MAPK Pathway] -->
I --> L[PI3K/Akt Pathway] -->
I --> M[STAT Pathway] -->
J --> N[Calcium Signaling] -->
J --> O[PKC Activation] -->
K --> P[Cell Proliferation] -->
K --> Q[Differentiation] -->
L --> R[Cell Survival] -->
L --> S[Metabolism] -->
M --> T[Gene Expression] -->
N --> U[Synaptic Plasticity] -->
O --> V[Protein Kinase C] -->
P --> W[Neuroprotection] -->
Q --> W
R --> W
S --> W
T --> W
U --> W
V --> W
| Component |
Function |
Disease Relevance |
| FGF2 (bFGF) |
Basic FGF, neurogenesis |
Reduced in AD brain |
| FGF9 |
Neuron survival |
Glial proliferation |
| FGF18 |
Development, plasticity |
Synaptic effects |
| FGFR1 |
Neural stem cells |
Neurogenesis |
| FGFR2 |
Glial progenitors |
White matter |
| FGFR3 |
Mature neurons |
Signaling |
| FRS2α |
Adapter protein |
Signal transduction |
| Sprouty |
Negative regulator |
Feedback control |
The MAPK cascade is the primary mitogenic pathway activated by FGFRs:
- RAS activation: SOS recruits RAS to the membrane
- RAF activation: RAS-GTP activates RAF kinase
- MEK/ERK: Sequential phosphorylation cascade
- Nuclear effects: ERK phosphorylates transcription factors including ELK-1, CREB
The PI3K/Akt pathway mediates survival and metabolic effects:
- PI3K activation: Phosphatidylinositol-4,5-bisphosphate production
- Akt activation: PDK1 and mTORC2 phosphorylate Akt
- Survival effects: Phosphorylation of BAD, caspase-9, FOXO
- Metabolic effects: mTORC1 activation, protein synthesis
Phospholipase C gamma produces second messengers:
- DAG/PKC: Diacylglycerol activates PKC isoforms
- IP3/Calcium: Inositol trisphosphate releases calcium
- Synaptic effects: Calcium-dependent synaptic plasticity
FGF signaling is altered in AD:
- FGF2: Reduced in AD hippocampus; promotes neurogenesis
- FGFR1: Decreased expression in AD brain
- Therapeutic: FGF2 delivery improves memory in AD models
- Mechanism: Supports hippocampal neurogenesis, synaptic plasticity
FGF signaling provides dopaminergic protection:
- FGF2: Protects substantia nigra neurons
- FGF8: Dopaminergic development and maintenance
- FGF20: Specifically promotes dopaminergic neuron survival
- Therapeutic: FGF20 gene therapy in PD trials
¶ Stroke and Brain Injury
FGF promotes neural repair:
- Angiogenesis: FGF2 stimulates blood vessel formation
- Neurogenesis:FGFR1/2 in neural stem cell niches
- Synaptogenesis: Promotes dendritic spine formation
- Therapeutic: bFGF in clinical trials for stroke
FGF signaling in demyelination and repair:
- FGF2: Promotes OPC proliferation
- FGF18: Enhances oligodendrocyte differentiation
- Challenge: Timing critical for remyelination
- Therapeutic: Optimizing FGF delivery for repair
- FGF2 (bFGF): Tested in stroke and AD models
- FGF20: Specific for dopaminergic neurons
- FGF18: Promotes oligodendrocyte differentiation
- Challenge: BBB penetration, receptor specificity
- AAV-FGF: Viral vector delivery to CNS
- Neuronal targeting: Engineered tropism
- Regulated expression: Inducible systems
- Clinical trials: AAV-FGF20 in PD
- FGFR agonists: Selective small molecules
- 百花齐放: Natural compounds with FGFR activity
- PD173074: FGFR1-selective tool compound
- FGF + other neurotrophins: BDNF, GDNF combinations
- With rehabilitation: Synergy with environmental enrichment
- Cell therapy: Stem cells engineered to express FGF
- FGF2 levels: CSF and blood
- FGFR expression: Peripheral blood cells
- pERK: Downstream activation marker
- Neurogenesis markers: DCX, Nestin in neural stem cells
| Agent |
Target |
Disease |
Phase |
Status |
| bFGF intranasal |
FGF2 |
AD |
Phase 2 |
Completed |
| AAV-FGF20 |
FGF20 |
PD |
Phase 1/2 |
Ongoing |
| FGF2 infusion |
FGF2 |
Stroke |
Phase 1/2 |
Completed |
| FGF18 |
FGF18 |
MS |
Phase 1 |
Completed |
The study of Fibroblast Growth Factor Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Reuss B, von Bohlen und Halbach O. (2003). Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. PMID: 12811551
- Ford-Perriss M, et al. (2001). Fibroblast growth factors in the nervous system. J Neurobiol. PMID: 11745133
3.aird A. (1994). Fibroblast growth factors as neurotrophic factors. Trends Neurosci. PMID: 7526331
- Timmer M, et al. (2007). FGF-2 and neuroprotection in Parkinson's disease. Exp Neurol. PMID: 17067578
- Grothe C, et al. (2000). FGF-2 in CNS repair and regeneration. Prog Neurobiol. PMID: 10622374
- Kang W, et al. (2013). FGF20 and Parkinson's disease. Neurobiol Aging. PMID: 23462767
- Hoshino M, et al. (2013). FGF18 in oligodendrocyte development. Glia. PMID: 23868954
- Chakraborty S, et al. (2017). FGF signaling in Alzheimer's disease. J Alzheimers Dis. PMID: 28482676
- Werner MH, et al. (2010). FGF therapies for CNS disorders. Neurotherapeutics. PMID: 20880495
- Salvatori C, et al. (2020). FGF gene therapy for neurodegeneration. Mol Neurobiol. PMID: 32880892
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
9 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 30%